Why did HeraMED (ASX:HMD) launch the Phase 1 pilot program?

HeraMED (ASX:HMD) launched the six-month pilot with Lee Health to evaluate its remote patient monitoring platform as part of a digital-first maternity care model.

What were the key patient adoption metrics for the HeraMED (ASX:HMD) trial?

The platform tested by HeraMED (ASX:HMD) recorded 44 patients completing virtual prenatal visits and achieved a 92% virtual adoption rate. The company stated that the trial also recorded a program net promoter score of 60.

How does the pilot program affect the appointment capacity of Lee Health?

HeraMED (ASX:HMD) reported that the care pathway could free three to five prenatal appointment slots per patient. According to company models, this improvement in operational efficiency creates 32 additional prenatal slots.

What is the next timeline milestone for the HeraMED (ASX:HMD) expansion?

HeraMED (ASX:HMD) and Lee Health are currently progressing final internal sign-offs for Phase 2 of the program. The company expects a formal decision regarding this rollout within the coming weeks.

How did the stock market respond to the HeraMED (ASX:HMD) announcement?

Following the operational announcement, the HeraMED (ASX:HMD) share price declined during market trading. The stock was down to close at a price of $0.036.

Image for illustrative purposes only. Not a real photo.

HeraMED completes pilot program with 44 patients

Written by Mahathir BayenaPublished Jul 14, 2026, 6:14 AM

HeraMED completed its six-month Phase 1 digital pregnancy journey pilot programme with US healthcare provider Lee Health.
The announcement coincided with a decline in the company's stock price to $0.036 during market trading.
The trial aimed to demonstrate clinical workflow efficiencies and increase appointment capacity through remote patient monitoring.

Medical technology company HeraMED (ASX:HMD) completed its six-month maternity pilot with US-based Lee Health across 44 patients.

The milestone follows the initial pilot agreement executed in late 2025 to test hybrid virtual care pathways.

"This is a significant milestone for HeraMED to partner with a nationally recognised major US healthcare provider," said HeraMED CEO Anoushka Gungadin.

The company stated that the platform achieved 92% virtual adoption and could free three to five appointment slots per patient.

Following the announcement, the HeraMED share price was down at $0.036.

The business previously advanced its remote monitoring footprint through partnerships with Mayo Clinic and Sheba Medical Centre.

Both groups are currently finalising internal sign-offs to decide on a Phase 2 rollout within the coming weeks.

HeraMED completes pilot program with 44 patients

Frequently asked questions

Assets related to this article